Scientific Information

Organising Institutions

International Foundation for Maternal Periconceptional and Peri- neonatal Medicine (FIMPP) founded by a group of highly professional and enthusiastic obstetricians and neonatologists, the worldwide known experts in the field that aim to revive the interest around maternal and neonatal care.
FIMPP is composed of Board of Directors, chaired by Prof. Gian Carlo Di Renzo from Italy and Board of Scientific Advisors, chaired by Prof. Umberto Simeoni from Switzerland.
The purpose of FIMPP is to foster education, research and advocacy in maternal, periconceptional and neonatal medicine and care worldwide. The Foundation aims to promote and disseminate the study, research and knowledge on the aspects of maternal, periconceptional and neonatal medicine, in order to attain, by appropriate means, a higher level of physical and mental health for women,
mothers, and their children.
Collaboration between various disciplines interested in maternal, perception, and perinatal care as well as friendship between individuals from different world countries will lead to improving the quality and provision of care in the world.

 

Birth and Culture – Nascita e Cultura

Nascita e Cultura is a non-profit association inspired by the values of scientific, deontological and bioethical culture in life sciences which aims to affirm, promote and enhance the global culture of the health of the mother, the fetus and the newborn, understood as the achievement of the highest degree of mental, physical and social well-being, according to the guidelines of the World Health Organization.

Congress Committees

Congress President
Invited Speakers
 
 
 
 
 

Scientific Programme

09:00-09:05

WELCOME FROM CONGRESS PRESIDENTS

Yves Ville, France

09:05-12:15

SESSION 1 - Asymptomatic children with cCMV

Moderators: Daniel Blázquez Gamero, Spain - Efraim Bilavsky, Israel

09:05-09:25

What is an asymptomatic neonate in 2021?

Daniel Blázquez Gamero, Spain

09:25-09:45

What can we offer to asymptomatic children with late onset hearing loss?

Ina Foulon, Belgium

09:45-10:05

Advanced imaging in fetal CMV infection

Chloe Arthuis, France

10:05-10:15

Panel Discussion

10:15-10:25

(ID 11) - Does universal newborn screening for congenital cytomegalovirus (cCMV) infection help? A cohort study from Qatar and Germany

Katrin Neumann, Germany

10:25-10:35

(ID 12) - Congenital CMV infection: a risk factor for neuro-psychological sequelae?

Arianna Turriziani Colonna, Italy

10:35-10:45

(ID 48) - Congenital CMV infection - 7 years experience in a Portuguese neonatal intensive care unit

Francisca Calheiros Trigo, Portugal

10:45-11:00

Discussion

11:00-11:30

COFFEE BREAK

11:30-11:40

(ID 16) Evolution of the intracranial features of congenital CMV in children

Jack Garnham, United Kingdom

11:40-11:50

(ID 42) Single Nucleotide Polymorphisms of Interleukins and Toll-like Receptors and Neuroimaging Results in Newborns with Congenital HCMV Infection

Justyna Czech-Kowalska, Poland

11:50-12:00

(ID 47) Newborns with Autism Spectrum Disorder: a link with congenital CMV?

Perrine Coste Mazeau, France

12:00-12:15

Discussion

12:15-13:00

DEBATE: UNIVERSAL NEONATAL SCREENING

Mark R. Schleiss, USA Vs. Daniel Blázquez Gamero, Spain

13:00-14:00

LUNCH / POSTER VIEWING

14:00-15:00

Congenital CMV infection: how to implement the diagnostics and the clinical follow up

industry supported session
CLICK HERE TO SEE SPONSORED SESSIONS PROGRAMME

15:00-15:35

ORAL COMMUNICATION Congenital CMV infection

15:00-15:10

(ID 31) - Prevalence and Clinical Characteristics of Congenital Cytomegalovirus Infection in a Population-Based Universal Newborn Screening Study in Minnesota

Mark Schleiss, United States

15:10-15:20

(ID 35) - Screening for congenital cytomegalovirus in preterm babies <30 weeks gestation

Helen Payne, United Kingdom

15:20-15:35

Discussion

15:35-16:00

COFFEE BREAK

16:00-17:30

SESSION 2 - Infection during pregnancy

Moderators: Tiziana Lazzaroto, Italy

16:00-16:20

Gestational age at maternal infection and postnatal outcome

Christos Chatzakis, Greece

16:20-16:40

The biological clock for maternal serology is ticking for prenatal screening

Marianne Leruez, France

16:40-17:00

Non-primary infections. Biological markers

Daniele Lilleri, Italy

17:00-17:10

(ID 8) - Cytomegalovirus non primary infection during pregnancy: retrospective serological and molecular analysis in 38 patients.

Claire Perillaud-Dubois, France

17:10-17:20

(ID 36) - CMV DNA in placentae from first trimester primary infection cases with or without fetal infection and with or without valaciclovir treatment

Jacques Fourgeaud, France

17:20-17:30

Discussion

17:30-18:30

DEBATE: Vaccines - adults or toddlers?

Yves Ville, France vs Efraim Bilavsky, Israel

09:00-12:00

SESSION 4 Fetal infection

Moderators: Karl Oliver Kagan, Germany

09:00-09:20

International registry on the use of valaciclovir for secondary prevention

Valentine Faure-Bardon, France

09:20-09:40

Hyperimmune globulins, how and how much

Karl Oliver Kagan, Germany

09:40-10:00

Screening in pregnancy, what can you get for your money?

Valérie Seror, France

10:00-10:20

Screening in pregnancy, why not then?

Anna Gonce, Spain

10:20-10:45

Discussion

10:45-11:15

COFFEE BREAK

11:15-12:00

DEBATE: Invasive Diagnosis the earlier the better

Yves Ville, France Vs. Schlomo Lipitz, Israel

12:00-12:20

Do we need to perform brain MRI in every infant with Ccmv?

Efi Bilavsky, Israel

12:20-13:30

LUNCH AND POSTER VIEWING

13:30-16:15

SESSION 5 - Hearing loss, vestibular disorders and rehabilitation in children with cCMV

Moderators: Ina Foulon, Belgium

13:00-13:20

Hearing loss in children with cCMV - from the broad spectrum to the individual

Blake Papsin, Canada

13:20-13:40

How do we diagnose and treat vestibular problems in children with CCMV?

Natacha Teissier, France

13:40-14:00

Hearing and vestibular rehabilitation in children with unilateral hearing loss

Blake Papsin, Canada

14:00-14:15

Discussion

14:15-14:25

(ID 10) - The CONCERT Study: Treatment of Infants with Congenital Cytomegalovirus Infection and Isolated Hearing Loss, Detected Through Newborn Hearing Screening

P.K. Chung, the Netherlands

14:25-14:35

(ID 4) - The effect of (val)ganciclovir on hearing in congenital cytomegalovirus: a systematic review.

Elise De Cuyper, Belgium

14:35-14:45

(ID 40) - Immunogenicity Findings From a Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an mRNA- Based Vaccine Against Cytomegalovirus Infection

Lori Panther, United States

14:45-14:55

(ID 43) - Universal newborn screening for congenital CMV infection: a prospective multicenter clinical trial

Liliana Gabrielli, Italy

14:55-15:05

(ID 49) - Prognostic value of mild cerebral features in infected fetuses treated in utero after maternal infection in the first trimester

N BOURGON, France

15:05-15:30

COFFEE BREAK

15:30-15:40

(ID 18) - Unmet needs in maternal diagnosis and treatment for congenital CMV in France: data from the French “congenital CMV declaration platform” of the National Reference Center for Herpesviruses

Elodie Ribot, France

15:40-15:50

(ID 22) Cortical maturation assessed by magnetic resonance imaging in unaffected/mildly affected fetuses with cytomegalovirus infection.

Ameth Hawkins-Villarreal, Spain

15:50-16:00

(ID 23) Performance of targeted congenital cytomegalovirus screening in newborns failing universal hearing screening: a multicenter study

Jacques Fourgeaud, France

16:00-16:15

Discussion

16:15-16:45

Anti-CMV Vaccines. Any lesson learned from the Covid pandemic?

Shilpe Sharma, Belgium

16:45-17:00

CLOSING REMARKS

Yves Ville, Efraim Bilavsky

Thursday, October 21

14:00-15:00

Congenital CMV infection: how to implement the diagnostics and the clinical follow up

14:00-14:50

Diagnosis of maternal CMV infection: lights and shadows

Tiziana Lazzarotto, Italy

14:20-14:40

Neonatal diagnosis of CMV congenital infection: current approach and pitfalls

Marianne Leruez-Ville, France

14:40-15:00

Hearing loss and clinical follow up in children with cCMV infection

Ina Foulon, Belgium

session supported by DiaSorin


Accreditations

Congress Topics

  • The risks in pregnancy are well defined
  • Screening and diagnostic tools are efficient, and quality control is effective
  • Primary prevention is part of preconceptional medicine
  • Vaccine technology has been revolutionized by the COVID pandemic
  • Diagnosis is as reliable prenatally and postnatally
  • Secondary and tertiary prevention are efficient and should be widely implemented
  • Postnatal care has been simplified and rationalized
  • Sensorineural hearing loss is not a fatality
  • Are there any late complications other than hearing impairment is asymptomatic children?
  • Sensorineural hearing loss is not a fatality
  • Hearing rehabilitation in cCMV children with unilateral hearing loss
  • Is there an association between CMV infections and ADD/Autism/Schizophrenia?
  • Brain imaging for children with cCMV – Ultrasound or MRI?
  • Universal screening for cCMV
  • Early diagnosis of cCMV using Chorionic villus sampling
  • Vestibular problems in symptomatic and asymptomatic cCMV
  • What can we offer to asymptomatic children with late onset hearing loss?